ConvaTec Group PLC (LON:CTEC) Given Average Recommendation of “Buy” by Brokerages

Shares of ConvaTec Group PLC (LON:CTEC) have earned an average recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is GBX 318.67.

A number of research firms recently issued reports on CTEC. UBS Group reiterated a “buy” rating and set a GBX 375 price objective on shares of ConvaTec Group in a research report on Friday, November 7th. Peel Hunt restated an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a research report on Thursday, November 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th.

ConvaTec Group Stock Up 0.3%

CTEC stock opened at GBX 232.20 on Wednesday. The stock has a market capitalization of £4.53 billion, a P/E ratio of 21.91, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. ConvaTec Group has a 12 month low of GBX 219.80 and a 12 month high of GBX 311.20. The firm has a 50-day moving average price of GBX 236.80 and a 200-day moving average price of GBX 238.07.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.